Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Genetic, biochemical, and anatomical grounds led to the proposal of the amyloid cascade hypothesis centered on the accumulation of amyloid beta peptides (Aβ) to explain Alzheimer's disease (AD) etiology. In this context, a bulk of efforts have aimed at developing therapeutic strategies seeking to reduce Aβ levels, either by blocking its production (γ- and β-secretase inhibitors) or by neutralizing it once formed (Aβ-directed immunotherapies). However, so far the vast majority of, if not all, clinical trials based on these strategies have failed, since they have not been able to restore cognitive function in AD patients, and even in many cases, they have worsened the clinical picture. We here propose that AD could be more complex than a simple Aβ-linked pathology and discuss the possibility that a way to reconcile undoubted genetic evidences linking processing of APP to AD and a consistent failure of Aβ-based clinical trials could be to envision the pathological contribution of the direct precursor of Aβ, the β-secretase-derived C-terminal fragment of APP, βCTF, also referred to as C99. In this review, we summarize scientific evidences pointing to C99 as an early contributor to AD and postulate that γ-secretase should be considered as not only an Aβ-generating protease, but also a beneficial C99-inactivating enzyme. In that sense, we discuss the limitations of molecules targeting γ-secretase and propose alternative strategies seeking to reduce C99 levels by other means and notably by enhancing its lysosomal degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329 · cited 1×
“Some C99 escapes from γ-secretase cleavage and is incorporated in ILVs (intra luminal vesicles), which are either released as exosomes after the fusion of multivesicular bodies (MVBs) with the plasma membrane (1) or degraded after their fusion of MVBs with lysosomes or with autophagosomes, which then fuse with lysosom…”
BackgroundNeurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
A Gene Network Regulating Lysosomal Biogenesis and Function
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D. L., Valenza, M., Gennarino, V. A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R. S., et al. (2009) · Science · doi:10.1126/science.1174447 · Cited by 2,543 · cited 2×
“Thus, a better way to enhance degradation could be to activate both autophagy and lysosomal function by overexpressing or pharmacologically activating the transcription factor EB (TFEB), the main regulator of the lysosomal/autophagic degradation pathway (191).”
BackgroundGoedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 6×
“Indeed, accumulating evidence indicates that both PS1 and PS2 are involved in essential cellular processes, independently of their role in γ-secretase, and proposed to be due notably to their function as chaperons and/or control of calcium release from the endoplasmic reticulum (for reviews see (75, 76)).”
BackgroundInfluentialNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 1×
“The definitive demonstration that presenilins could be involved in γ-secretase activity came from subsequent functional characterization showing that their depletion fully prevents Aβ production (45, 46).”
BackgroundCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 3×
“Furthermore, the identification of APP mutations responsible for autosomal dominant form of AD (FAD), including the “Dutch” (9) “London” (10) and “Swedish” mutations (11), showed that the functional consequences of these mutations were to augment the load of Aβ and/or to shift Aβ production to more aggregating Aβ pept…”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663 · cited 1×
“The latter statement is of importance due to the proposed role of exosomes in prion-like transmission of neurotoxic molecules (148).”
BackgroundMullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · cited 1×
“Furthermore, the identification of APP mutations responsible for autosomal dominant form of AD (FAD), including the “Dutch” (9) “London” (10) and “Swedish” mutations (11), showed that the functional consequences of these mutations were to augment the load of Aβ and/or to shift Aβ production to more aggregating Aβ pept…”
BackgroundBorchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“Thus, Aβ should be considered firstly as a physiological product derived from normal processing of APP (78, 79).”
BackgroundMembrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“Active immunotherapy AN-1792 (synthetic Aβ42, Janssen) ≥ 60–70% Aβ load reduction in the brain (post-mortem immonustaining) Discontinued in 2002 (mild to moderate AD patients) Meningoencephalitis (208) (209) (210) CAD106 (multiple copies of Aβ1-6 peptide, Novartis) 1.”
BackgroundNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 2×
“Although a huge effort has been made to try Table 1 Principal antiamyloid clinical drugs and strategies Strategy Drug/specific target Aβ modulation in treated AD patients FDA statute and participants Side effects/cognitive readout Reference Active immunotherapy AN-1792 (synthetic Aβ42, Janssen) ≥ 60–70% Aβ load reduct…”
BackgroundInfluentialA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183 · cited 1×
“However, some later studies analyzed C99 levels and reported also an increase in both FAD and SAD brains (137, 138, 175).”
BackgroundIdentification of a Novel Aspartic Protease (Asp 2) as β-Secretase
Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., et al. (1999) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1999.0811 · Cited by 1,080
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“Solanezumab (monomeric and soluble forms of Aβ Eli Lilly) 170- and 18-fold increase in plasma Aβ40 and Aβ42 respectively no Aβ modulation in brain PET scan (florbetapir) at 400 mg Phase III ongoing in asymptomatic people who have biomarker evidence of brain amyloid deposition Lack of efficacy in mild to moderate AD an…”
BackgroundSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991
Self-citationA critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Skeletal and CNS Defects in Presenilin-1-Deficient Mice
Shen, J., Bronson, R. T., Chen, D. F., Xia, W., Selkoe, D. J., & Tonegawa, S. (1997) · Cell · doi:10.1016/s0092-8674(00)80244-5 · Cited by 959
Release of Excess Amyloid β Protein from a Mutant Amyloid β Protein Precursor
Cai, X.-D., Golde, T. E., & Younkin, S. G. (1993) · Science · doi:10.1126/science.8424174 · Cited by 913 · cited 3×
“Furthermore, the identification of APP mutations responsible for autosomal dominant form of AD (FAD), including the “Dutch” (9) “London” (10) and “Swedish” mutations (11), showed that the functional consequences of these mutations were to augment the load of Aβ and/or to shift Aβ production to more aggregating Aβ pept…”
BackgroundThe case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 1×
“This has led to question the validity of the amyloid cascade hypothesis (23) or to discuss in a more cautious and balanced manner the ins, outs, and limitations of the procedures of clinical trials (24).”
BackgroundSaura, C. A., Choi, S.-Y., Beglopoulos, V., Malkani, S., Zhang, D., Rao, B. S. S., Chattarji, S., Kelleher, R. J., Kandel, E. R., Duff, K., et al. (2004) · Neuron · doi:10.1016/s0896-6273(04)00182-5 · Cited by 757 · cited 1×
“invalidation of γ-secretase in mice is lethal (84) and that the conditional knockout of PS1 leads to neurodegeneration at the adulthood (85).”
BackgroundElevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729
Molecular genetics of early-onset Alzheimer’s disease revisited
Cacace, R., Sleegers, K., & Van Broeckhoven, C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.012 · Cited by 617 · cited 1×
“FAD cases correspond to only a very small subset of patients (about 1%) (77).”
BackgroundIncreased expression of the amyloid precursor β‐secretase in Alzheimer's disease
Holsinger, R. M. D., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002) · Annals of Neurology · doi:10.1002/ana.10208 · Cited by 562
The Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545 · cited 1×
“β-secretase inhibitors Verubecestat (MK8931Merck) ≥ 57–84% Aβ reduction in CSF at 12–60 mg Discontinued in 2018 (prodromal, mild to moderate AD patients) Worsens cognition, anxiety, depression, and sleep problems (217) (218)”
BackgroundThe mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495 · cited 1×
“Therefore, several groups started to screen for drugs having a higher affinity for APP than toward Notch, such as Avagacestat, initially reported to be 140-fold more selective for APP than Notch (113), although its Notch sparing ability remains controversial (114, 115).”
BackgroundShen, J., & Kelleher, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608332104 · Cited by 485 · cited 1×
“On the other hand, Shen and Kelleher proposed an alternative hypothesis “the presenilin hypothesis,” stating that loss of general PS function should be the trigger of neurodegeneration and defects in cognitive function (57).”
BackgroundKent, S. A., Spires-Jones, T. L., & Durrant, C. S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02196-w · Cited by 446
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 1×
“Gantenerumab (oligomers, and fibrils of Aβ, Roche) ≥ 15%, 35% and 78% Aβ reduction in brain PET scan (florbetapir) at 60, 200 and 1200 mg respectively Phase III ongoing in an openlabel extension study in mild to moderate AD patients (SCarlet RoAD, Marguerite RoAD, and GRADUATE) and in asymptomatic carriers of APP and…”
BackgroundNixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400
η-Secretase processing of APP inhibits neuronal activity in the hippocampus
Willem, M., Tahirovic, S., Busche, M. A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L. D. B., Moore, S., Daria, A., et al. (2015) · Nature · doi:10.1038/nature14864 · Cited by 398 · cited 1×
“A recent study also proposed another neuroprotective role of BACE1, since the inhibition of this enzyme was found to enhance the levels of both ƞ-secretase and Aƞα, the latter was proposed to be neurotoxic (27).”
BackgroundChui, D.-H., Tanahashi, H., Ozawa, K., Ikeda, S., Checler, F., Ueda, O., Suzuki, H., Araki, W., Inoue, H., Shirotani, K., et al. (1999) · Nature Medicine · doi:10.1038/8438 · Cited by 364
Self-citationCaccamo, A., Magrì, A., Medina, D. X., Wisely, E. V., López‐Aranda, M. F., Silva, A. J., & Oddo, S. (2013) · Aging Cell · doi:10.1111/acel.12057 · Cited by 362
Lee, J.-H., McBrayer, M. K., Wolfe, D. M., Haslett, L. J., Kumar, A., Sato, Y., Lie, P. P. Y., Mohan, P., Coffey, E. E., Kompella, U., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.050 · Cited by 358 · cited 1×
“In addition, pharmacological treatments such as acidic nanoparticles, PLGA (poly lactic-coglycolic acid, called acidic nanoparticles (196) could constitute an alternative way to increase lysosomal function.”
BackgroundA γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
Brothers, H. M., Gosztyla, M. L., & Robinson, S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00118 · Cited by 314
Cognitive deficits in single App knock-in mouse models
Masuda, A., Kobayashi, Y., Kogo, N., Saito, T., Saido, T. C., & Itohara, S. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.07.001 · Cited by 248 · cited 1×
“In fact, the two knock-in models APP-NL and APP-NL-F, harboring the Swedish (KM670/671NL) mutation alone (APP-NL), or in combination with the I706F mutation (APP-NL-F), respectively, both accumulate C99 (132), but only the APP-NL-F, displaying higher Aβ levels, develops late-stage cognitive dysfunction (132, 169).”
BackgroundLauritzen, I., Pardossi-Piquard, R., Bourgeois, A., Pagnotta, S., Biferi, M.-G., Barkats, M., Lacor, P., Klein, W., Bauer, C., & Checler, F. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1577-6 · Cited by 219
Self-citationKlein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212 · cited 1×
“Gantenerumab (oligomers, and fibrils of Aβ, Roche) ≥ 15%, 35% and 78% Aβ reduction in brain PET scan (florbetapir) at 60, 200 and 1200 mg respectively Phase III ongoing in an openlabel extension study in mild to moderate AD patients (SCarlet RoAD, Marguerite RoAD, and GRADUATE) and in asymptomatic carriers of APP and…”
BackgroundMitani, Y., Yarimizu, J., Saita, K., Uchino, H., Akashiba, H., Shitaka, Y., Ni, K., & Matsuoka, N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4264-11.2012 · Cited by 203 · cited 9×
“in AD animal models, the chronic treatment with GSMs did not lead to the worsening of cognitive function observed with GSIs (117).”
BackgroundInfluentialLauritzen, I., Pardossi-Piquard, R., Bauer, C., Brigham, E., Abraham, J.-D., Ranaldi, S., Fraser, P., St-George-Hyslop, P., Le Thuc, O., Espin, V., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2775-12.2012 · Cited by 201
Self-citationPreliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease
Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813435 · Cited by 197 · cited 1×
“Atabecestat (Janssen) ≥ 67–90% Aβ reduction in CSF at 10–50 mg Discontinued in 2018 (asymptomatic people) Worsens cognition, elevated liver enzymes, depression, anxiety, and sleep problems (219) (220)”
BackgroundThe BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177 · cited 1×
“Umibecestat (Novartis) ≥ 90% Aβ reduction in CSF at 85 mg Discontinued in 2019 (asymptomatic carriers of APOE-4) Worsens cognition, brain atrophy and weight loss (223) (187) www.”
BackgroundDourlen, P., Kilinc, D., Malmanche, N., Chapuis, J., & Lambert, J.-C. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02004-0 · Cited by 168
Presenilin-Dependent -Secretase-Mediated Control of p53-Associated Cell Death in Alzheimer's Disease
Alves da Costa, C., Sunyach, C., Pardossi-Piquard, R., Sevalle, J., Vincent, B., Boyer, N., Kawarai, T., Girardot, N., St. George-Hyslop, P., & Checler, F. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0651-06.2006 · Cited by 168 · cited 1×
“This phenomenon is also described for APP for which the intracellular domain AICD has been found to form a transcriptional active complex with Fe65 and Tip60 (98, 99) that regulates key proteins involved in the control of cell death (p53) (100), Aβ degradation (Neprilysin) (101, 102), as well as tau phosphorylation (G…”
BackgroundSelf-citationLysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99)
Jiang, Y., Sato, Y., Im, E., Berg, M., Bordi, M., Darji, S., Kumar, A., Mohan, P. S., Bandyopadhyay, U., Diaz, A., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.0578-19.2019 · Cited by 166
Hung, C. O. Y., & Livesey, F. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.095 · Cited by 159
Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease
Szaruga, M., Veugelen, S., Benurwar, M., Lismont, S., Sepulveda-Falla, D., Lleo, A., Ryan, N. S., Lashley, T., Fox, N. C., Murayama, S., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150892 · Cited by 155 · cited 2×
“In contrast, Szaruga and colleagues (61) measured γ-secretase activity in brain extracts from patients carrying PS1 mutations (one healthy and one disease allele) and found a variable effect on endopeptidase cleavage but a consistent reduction in carboxypeptidase activity, seen as Aβ38/Aβ42.”
BackgroundResultWakabayashi, T., Craessaerts, K., Bammens, L., Bentahir, M., Borgions, F., Herdewijn, P., Staes, A., Timmerman, E., Vandekerckhove, J., Rubinstein, E., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1978 · Cited by 135
Investigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132 · cited 1×
“6% Aβ reduction in brain PET scan (florbetaben and florbetapir respectively) at 50 mg Discontinued in 2019 (prodromal, mild to moderate AD patients) Weight loss, skin rashes and neuropsychiatric adverse events (224) (225) JB C R EV EW S: γ-Seetase:a bene ficialCinactivating ezym e J.”
BackgroundLopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116 · cited 2×
“in CSF but was stopped due to deleterious cognitive and side effects (187).”
BackgroundINTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
Meyer, P.-F., Tremblay-Mercier, J., Leoutsakos, J., Madjar, C., Lafaille-Maignan, M.-É., Savard, M., Rosa-Neto, P., Poirier, J., Etienne, P., Breitner, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007232 · Cited by 113
Timmers, M., Streffer, J. R., Russu, A., Tominaga, Y., Shimizu, H., Shiraishi, A., Tatikola, K., Smekens, P., Börjesson-Hanson, A., Andreasen, N., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0415-6 · Cited by 112 · cited 1×
“Atabecestat (Janssen) ≥ 67–90% Aβ reduction in CSF at 10–50 mg Discontinued in 2018 (asymptomatic people) Worsens cognition, elevated liver enzymes, depression, anxiety, and sleep problems (219) (220)”
BackgroundBoche, D., Donald, J., Love, S., Harris, S., Neal, J. W., Holmes, C., & Nicoll, J. A. R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0705-y · Cited by 85 · cited 1×
“Active immunotherapy AN-1792 (synthetic Aβ42, Janssen) ≥ 60–70% Aβ load reduction in the brain (post-mortem immonustaining) Discontinued in 2002 (mild to moderate AD patients) Meningoencephalitis (208) (209) (210) CAD106 (multiple copies of Aβ1-6 peptide, Novartis) 1.”
BackgroundCacquevel, M., Aeschbach, L., Houacine, J., & Fraering, P. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035133 · Cited by 75
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Kwart, D., Gregg, A., Scheckel, C., Murphy, E. A., Paquet, D., Duffield, M., Fak, J., Olsen, O., Darnell, R. B., & Tessier-Lavigne, M. (2019) · Neuron · doi:10.1016/j.neuron.2019.11.010 · Cited by 70
γ-Secretase and its modulators: Twenty years and beyond
Xia, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.011 · Cited by 54
Tambini, M. D., Yao, W., & D'Adamio, L. (2019) · Aging Cell · doi:10.1111/acel.13033 · Cited by 40 · cited 1×
“It should be emphasized that two recent studies documented that BACE may inactivate an intravesicular domain of APP, thereby exacerbating glutamate release (179), a process enhanced in a rat knock-in model bearing the Swedish mutation (135).”
Background
Cited by
Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases
Nixon, R. A., & Rubinsztein, D. C. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00757-5 · Cited by 435
“3), coupled with multiple genetic, environmental and cell ageing factors 121,132,133,135,136,139,280–292 , begins to corrupt lysosomal function at the earliest stage of the disease and before signs of neuropathology appear.”
Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches
Mary, A., Eysert, F., Checler, F., & Chami, M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01631-6 · Cited by 244
“Accordingly, C99 accumulation was found to occur in several AD transgenic mice models and in APP KI mice harboring single or several APP FAD mutations [43].”
Self-citationIm, E., Jiang, Y., Stavrides, P. H., Darji, S., Erdjument-Bromage, H., Neubert, T. A., Choi, J. Y., Wegiel, J., Lee, J.-H., & Nixon, R. A. (2023) · Science Advances · doi:10.1126/sciadv.adg1925 · Cited by 80
Jordà‐Siquier, T., Petrel, M., Kouskoff, V., Smailovic, U., Cordelières, F., Frykman, S., Müller, U., Mulle, C., & Barthet, G. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12546 · Cited by 63
Hermey, G., & Klein, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.361544 · Cited by 10
“APP, a type-I transmembrane protein, is sequentially processed by different enzymes in alternative pathways (Eggert et al., 2018; Checler et al., 2021).”
Background
Metadata
- Authors
- Checler, F., Afram, E., Pardossi-Piquard, R., & Lauritzen, I.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 296
- Pages
- 100489
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W3135391394
- Cited by
- 59
- References
- 70
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.